Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response

被引:592
作者
Vaupel, P
Harrison, L
机构
[1] Johannes Gutenberg Univ Mainz, Inst Physiol & Pathophysiol, D-55099 Mainz, Germany
[2] Beth Israel Deaconess Med Ctr, New York, NY USA
关键词
tumor hypoxia; causative factors; cellular response; malignant progression; biology; anemia; hemoglobin;
D O I
10.1634/theoncologist.9-90005-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Hypoxia is a characteristic feature of locally advanced solid tumors resulting from an imbalance between oxygen (O-2) supply and consumption. Major causative factors of tumor hypoxia are abnormal structure and function of the microvessels supplying the tumor, increased diffusion distances between the nutritive blood vessels and the tumor cells, and reduced O-2 transport capacity of the blood due to the presence of disease- or treatment-related anemia. Tumor hypoxia is a therapeutic concern since it can reduce the effectiveness of radiotherapy, some O-2-dependent cytotoxic agents, and photodynamic therapy. Tumor hypoxia can also negatively impact therapeutic outcome by inducing changes in the proteome and genome of neoplastic cells that further survival and malignant progression by enabling the cells to overcome nutritive deprivation or to escape their hostile environment. The selection and clonal expansion of these favorably altered cells further aggravate tumor hypoxia and support a vicious circle of increasing hypoxia and malignant progression while concurrently promoting the development of more treatment-resistant disease. This pattern of malignant progression, coupled with the demonstration of a relationship between falling hemoglobin level and worsening tumor oxygenation, highlights the need for effective treatment of anemia as one approach for correcting anemic hypoxia in tumors, and in so doing, possibly improving therapeutic response.
引用
收藏
页码:4 / 9
页数:6
相关论文
共 29 条
[1]
Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas [J].
Becker, A ;
Stadler, P ;
Lavey, RS ;
Hänsgen, G ;
Kuhnt, T ;
Lautenschläger, C ;
Feldmann, HJ ;
Molls, M ;
Dunst, J .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (02) :459-466
[2]
DEMICHELI R, 1994, J NATL CANCER I, V86, P45
[3]
THE INFLUENCE OF MICROENVIRONMENTAL FACTORS ON THE ACTIVITY OF RADIATION AND DRUGS - KEYNOTE ADDRESS [J].
DURAND, RE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (02) :253-258
[4]
Seminars in medicine of the Beth Israel Hospital, Boston - Clinical applications of research on angiogenesis [J].
Folkman, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (26) :1757-1763
[5]
Hypoxic stress proteins: Survival of the fittest [J].
Giaccia, AJ .
SEMINARS IN RADIATION ONCOLOGY, 1996, 6 (01) :46-58
[6]
Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia [J].
Goda, N ;
Ryan, HE ;
Khadivi, B ;
McNulty, W ;
Rickert, RC ;
Johnson, RS .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (01) :359-369
[7]
THE CONCENTRATION OF OXYGEN DISSOLVED IN TISSUES AT THE TIME OF IRRADIATION AS A FACTOR IN RADIOTHERAPY [J].
GRAY, LH ;
CONGER, AD ;
EBERT, M ;
HORNSEY, S ;
SCOTT, OCA .
BRITISH JOURNAL OF RADIOLOGY, 1953, 26 (312) :638-648
[8]
Early wound healing exhibits cytokine surge without evidence of hypoxia [J].
Haroon, ZA ;
Raleigh, JA ;
Greenberg, CS ;
Dewhirst, MW .
ANNALS OF SURGERY, 2000, 231 (01) :137-147
[9]
Biological consequences of tumor hypoxia [J].
Höckel, M ;
Vaupel, P .
SEMINARS IN ONCOLOGY, 2001, 28 (02) :36-41
[10]
Tumor hypoxia:: Definitions and current clinical, biologic, and molecular aspects [J].
Höckel, M ;
Vaupel, P .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04) :266-276